5928-35-8

Basic information

• Product Name: 4H-1-Benzopyran-4-one, 5,6-dihydroxy-2-phenyl-7-(phenylmethoxy)-
• CAS NO: 5928-35-8
• Molecular Formula: C22H16O5
• Molecular Weight: 360.366
• Mol File: 5928-35-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4H-1-Benzopyran-4-one, 5,6-dihydroxy-2-phenyl-7-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-1-Benzopyran-4-one, 5,6-dihydroxy-2-phenyl-7-(phenylmethoxy)-(5928-35-8)
• EPA Substance Registry System: 4H-1-Benzopyran-4-one, 5,6-dihydroxy-2-phenyl-7-(phenylmethoxy)-(5928-35-8)

Safety Data

• Hazardous Substances Data: 5928-35-8(Hazardous Substances Data)

Upstream product

• 491-67-8 5,6,7-trihydroxy-2-phenyl-4H-1-benzopyran-4-one 
• 67047-06-7 7-(benzyloxy)-4-oxo-2-phenyl-4H-1-benzopyran-5,6-diyl diacetate 
• 100-39-0 benzyl bromide 
• 21967-41-9 baicalin 
• 67047-05-6 4-oxo-2-phenyl-4H-1-benzopyran-5,6,7-triyl triacetate 

Downstream Products

• 67047-08-9 6-Benzoyloxy-7-benzyloxy-5-hydroxyflavon 
• 35990-03-5 Baicalein-6-O-β-D-glucopyranosiduronsaeure 
• 67047-10-3 5,7-Dibenzyloxy-6-hydroxyflavon 
• 28279-72-3 baicalein 6-O-β-D-glucopyranoside 
• 67047-09-0 6-Benzoyloxy-5,7-dibenzyloxyflavon 
• 74293-56-4 5,7-Dibenzyloxy-6-hydroxyflavon-6-O-β-D-glucopyranosid 
• 74293-59-7 5,7-Dibenzyloxy-6-hydroxyflavon-6-O-β-D-glucopyranosiduronsaeure 
• 74293-58-6 5,7-Dibenzyloxy-6-hydroxyflavon-6-O-(2,3,4-tri-O-acetyl-β-D-glucopyranosiduronsaeure-methylester) 
• 1272971-84-2 5-hydroxy-6-(2-morpholin-4-yl-ethoxy)-7-benzyloxy-flavone 
• 1345982-19-5 5,7-dihydroxy-6-(2-morpholin-4-yl-ethoxy)-flavone 
• 1263322-72-0 7-(benzyloxy)-6-(3-(dimethylamino)-propoxy)-5-hydroxy-2-phenyl-4H-chromen-4-one 
• 1263322-73-1 7-(benzyloxy)-5-hydroxy-2-phenyl-6-(3-(pyrrolidin-1-yl)propoxy)-4H-chromen-4-one 
• 1263322-74-2 C₃₀H₃₁NO₅ 
• 1263322-75-3 C₂₉H₂₉NO₆ 

Relevant articles and documents

Design, synthesis, and primary activity assays of baicalein derivatives as cyclin-dependent kinase 1 inhibitors

Malignant tumor is a disease with high mortality. Traditional treatment methods have many disadvantages, such as side-effects, drug resistance. Because cyclin-dependent kinase 1 (CDK1) plays an indispensable role in cell cycle regulation, it became an att

Anti-angiogenic and anticancer effects of baicalein derivatives based on transgenic zebrafish model

Angiogenesis leads to tumor neovascularization by promoting tumor growth and metastatic spread, therefore, angiogenesis is considered as an attractive target for potential small molecule anticancer drug discovery. Herein, we report the structural modification and biological evaluation of baicalein derivatives, among which compound 42 had potent in vivo anti-angiogenic activity and wide security treatment window in transgenic zebrafish model. Further, 42 exhibited the most potent inhibitory activity on HUVEC proliferation, migration and tube formation in vitro. Moreover, 42 significantly inhibited growth of human lung cancer A549 cells and weak influence on human normal fibroblast L929 cells. The present research demonstrated that the significant anti-angiogenic and anticancer effects, which provided the supportive evidence for 42 could be used as a potential compound of cancer therapy.

Novel synthetic baicalein derivatives caused apoptosis and activated AMP-activated protein kinase in human tumor cells

Studies on the anti-proliferative activities of novel baicalein derivatives demonstrated that compounds 8 and 9 were able to activate AMPK by enhancing the levels of phosphorylated AMPKα, and showed more potent anti-proliferative effects than baicalein an